Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed or Refractory Hodgkins Lymphoma

Trial Profile

A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed or Refractory Hodgkins Lymphoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Acronyms Nivo40
  • Most Recent Events

    • 17 Jun 2022 Results assessing the comparison of efficacy of Nivolumab 40 Mg expanded prospective cohort with the retrospective group of patients treated with Nivo 3 mg/kg presented at the 27th Congress of the European Haematology Association.
    • 08 Dec 2020 Results assessing efficacy and safety of nivolumab 40 mg in relapsed or refractory Classical Hodgkin Lymphoma, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 21 Jun 2020 Results (N=9) of NCT03343665 and NCT03259529 assessing Overall response rate of Immunotherapy with Nivolumab in Patients with Relapsed/Refractory Hiv-Related Lymphomas, presented at the 25th Congress of the European Haematology Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top